The advent of high throughput sequencing technologies has afforded an unprecedented understanding of the landscape of genomic and genetic alterations that occur in urothelial cancers. These efforts have not only provided an understanding of the pathogenesis of urothelial cancer but have also led to the identification of novel therapeutic targets. While the use of therapies individualized to a tumor’s molecular composition remains experimental for patients with urothelial cancer, a number of such treatments are well poised for near-term inclusion in standard therapeutic approaches. In this section we discuss several novel drugs on the horizon for treating advanced urothelial cancer.

Original languageEnglish
Title of host publicationBladder Cancer
Subtitle of host publicationA Practical Guide
PublisherSpringer International Publishing
Number of pages8
ISBN (Electronic)9781484271070
ISBN (Print)9781484271063
StatePublished - 1 Jan 2021


  • Antibody drug conjugates
  • FGFR
  • Nectin-4
  • PARP
  • Trop-2
  • Tyrosine kinase inhibitors
  • VEGF
  • mTOR


Dive into the research topics of 'Novel Therapies'. Together they form a unique fingerprint.

Cite this